UK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including ...

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...

The series B fundraising will support the clinical development of next-generation multivalent vaccines against respiratory ...

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

Vicebio has secured $100mn in Series B funding to further develop its vaccines for multiple respiratory infections.

The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said ...

Vicebio Ltd ("Vicebio"), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, today announces a $100 million Series B financing led by TCGX with ...

But lurking in the shadows is a more sinister threat: respiratory syncytial virus, or RSV. Cases begin to rise in September and is at its worst during the winter. Often dismissed as just another ...

But lurking in the shadows is a more sinister threat: respiratory syncytial virus, or RSV. Cases begin to rise in September and is at its worst during the winter. Often dismissed as just another ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, hospitalizations, lost quality of life, and deaths, according to one study.

Everyone age 60 and older who is at risk for getting very sick from RSV can get vaccinated, after talking with their doctor. Everyone age 60 and older who is at risk for getting very sick from RSV can ...

Covid-19 levels in the United States are high and rising, flu season is approaching quickly, and RSV cases are already starting to tick up. Forecasts from the US Centers for Disease Control and ...